BACKGROUND: Few studies have examined gene-specific associations with contralateral and/or second breast cancer (SBC). METHODS: The frequency of pathogenic and likely pathogenic (P/LP) variants in clinically actionable genes (BRCA1, BRCA2, PTEN, TP53, CHEK2, CDH1, ATM, PALB2, NBN, and NF1) was compared between women with a primary breast cancer (PBC) and SBC who underwent multigene panel testing at a single diagnostic testing laboratory. Race- and ethnicity-specific logistic regression burden tests adjusted for age at diagnosis of first breast cancer, histology, presence of first- or second-degree relatives with breast cancer, and prior testing for BRCA1/2 genes were used to test for associations with SBC. All statistical tests were 2-sided. RESULTS: The study was comprised of 75 550 women with PBC and 7728 with SBC. Median time between breast cancers for SBC was 11 (interquartile range = 6-17) years. Restricting to women tested for all actionable genes (n = 60 310), there were 4231 (7.8%) carriers of P/LP variants in actionable genes among the controls (PBC) compared with 652 (11.1%) women with SBC (P< .001). Among Caucasians, exclusive of Ashkenazi Jewish women, those carrying a P/LP variant in a clinically actionable gene were 1.44 (95% confidence interval [CI] = 1.30 to 1.60) times as likely to have SBC than noncarriers, after accounting for potential confounders. Among African American and Hispanic women, a P/LP variant in a clinically actionable gene was 1.88 (95% CI = 1.36 to 2.56) and 1.66 (9% CI = 1.02 to 2.58) times as likely to be associated with SBC, respectively (P < .001 and P = .03). CONCLUSION: Women with P/LP variants in breast cancer predisposition genes are more likely to have SBC than noncarriers. Prospective studies are needed confirm these findings.
BACKGROUND: Few studies have examined gene-specific associations with contralateral and/or second breast cancer (SBC). METHODS: The frequency of pathogenic and likely pathogenic (P/LP) variants in clinically actionable genes (BRCA1, BRCA2, PTEN, TP53, CHEK2, CDH1, ATM, PALB2, NBN, and NF1) was compared between women with a primary breast cancer (PBC) and SBC who underwent multigene panel testing at a single diagnostic testing laboratory. Race- and ethnicity-specific logistic regression burden tests adjusted for age at diagnosis of first breast cancer, histology, presence of first- or second-degree relatives with breast cancer, and prior testing for BRCA1/2 genes were used to test for associations with SBC. All statistical tests were 2-sided. RESULTS: The study was comprised of 75 550 women with PBC and 7728 with SBC. Median time between breast cancers for SBC was 11 (interquartile range = 6-17) years. Restricting to women tested for all actionable genes (n = 60 310), there were 4231 (7.8%) carriers of P/LP variants in actionable genes among the controls (PBC) compared with 652 (11.1%) women with SBC (P< .001). Among Caucasians, exclusive of Ashkenazi Jewish women, those carrying a P/LP variant in a clinically actionable gene were 1.44 (95% confidence interval [CI] = 1.30 to 1.60) times as likely to have SBC than noncarriers, after accounting for potential confounders. Among African American and Hispanic women, a P/LP variant in a clinically actionable gene was 1.88 (95% CI = 1.36 to 2.56) and 1.66 (9% CI = 1.02 to 2.58) times as likely to be associated with SBC, respectively (P < .001 and P = .03). CONCLUSION: Women with P/LP variants in breast cancer predisposition genes are more likely to have SBC than noncarriers. Prospective studies are needed confirm these findings.
Authors: Sarah T Hawley; Reshma Jagsi; Monica Morrow; Nancy K Janz; Ann Hamilton; John J Graff; Steven J Katz Journal: JAMA Surg Date: 2014-06 Impact factor: 14.766
Authors: Leona Bessonova; Thomas H Taylor; Rita S Mehta; Jason A Zell; Hoda Anton-Culver Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-01-07 Impact factor: 4.254
Authors: Jonine L Bernstein; Robert W Haile; Marilyn Stovall; John D Boice; Roy E Shore; Bryan Langholz; Duncan C Thomas; Leslie Bernstein; Charles F Lynch; Jorgen H Olsen; Kathleen E Malone; Lene Mellemkjaer; Anne-Lise Borresen-Dale; Barry S Rosenstein; Sharon N Teraoka; Anh T Diep; Susan A Smith; Marinela Capanu; Anne S Reiner; Xiaolin Liang; Richard A Gatti; Patrick Concannon Journal: J Natl Cancer Inst Date: 2010-03-19 Impact factor: 13.506
Authors: Akiko Chiba; Tanya L Hoskin; Emily J Hallberg; Jodie A Cogswell; Courtney N Heins; Fergus J Couch; Judy C Boughey Journal: Ann Surg Oncol Date: 2016-06-23 Impact factor: 5.344
Authors: Allison W Kurian; Emily E Hare; Meredith A Mills; Kerry E Kingham; Lisa McPherson; Alice S Whittemore; Valerie McGuire; Uri Ladabaum; Yuya Kobayashi; Stephen E Lincoln; Michele Cargill; James M Ford Journal: J Clin Oncol Date: 2014-04-14 Impact factor: 44.544
Authors: Douglas F Easton; Paul D P Pharoah; Antonis C Antoniou; Marc Tischkowitz; Sean V Tavtigian; Katherine L Nathanson; Peter Devilee; Alfons Meindl; Fergus J Couch; Melissa Southey; David E Goldgar; D Gareth R Evans; Georgia Chenevix-Trench; Nazneen Rahman; Mark Robson; Susan M Domchek; William D Foulkes Journal: N Engl J Med Date: 2015-05-27 Impact factor: 91.245
Authors: Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm Journal: Genet Med Date: 2015-03-05 Impact factor: 8.822
Authors: Maren Weischer; Børge G Nordestgaard; Paul Pharoah; Manjeet K Bolla; Heli Nevanlinna; Laura J Van't Veer; Montserrat Garcia-Closas; John L Hopper; Per Hall; Irene L Andrulis; Peter Devilee; Peter A Fasching; Hoda Anton-Culver; Diether Lambrechts; Maartje Hooning; Angela Cox; Graham G Giles; Barbara Burwinkel; Annika Lindblom; Fergus J Couch; Arto Mannermaa; Grethe Grenaker Alnæs; Esther M John; Thilo Dörk; Henrik Flyger; Alison M Dunning; Qin Wang; Taru A Muranen; Richard van Hien; Jonine Figueroa; Melissa C Southey; Kamila Czene; Julia A Knight; Rob A E M Tollenaar; Matthias W Beckmann; Argyrios Ziogas; Marie-Rose Christiaens; Johanna Margriet Collée; Malcolm W R Reed; Gianluca Severi; Frederik Marme; Sara Margolin; Janet E Olson; Veli-Matti Kosma; Vessela N Kristensen; Alexander Miron; Natalia Bogdanova; Mitul Shah; Carl Blomqvist; Annegien Broeks; Mark Sherman; Kelly-Anne Phillips; Jingmei Li; Jianjun Liu; Gord Glendon; Caroline Seynaeve; Arif B Ekici; Karin Leunen; Mieke Kriege; Simon S Cross; Laura Baglietto; Christof Sohn; Xianshu Wang; Vesa Kataja; Anne-Lise Børresen-Dale; Andreas Meyer; Douglas F Easton; Marjanka K Schmidt; Stig E Bojesen Journal: J Clin Oncol Date: 2012-10-29 Impact factor: 44.544
Authors: Fei Chen; Sungshim L Park; Lynne R Wilkens; Peggy Wan; Steven N Hart; Chunling Hu; Siddhartha Yadav; Fergus J Couch; David V Conti; Adam J de Smith; Christopher A Haiman Journal: Cancer Res Date: 2022-09-16 Impact factor: 13.312
Authors: Robert S Miller; Stella Mokiou; Aliki Taylor; Ping Sun; Katherine Baria Journal: Breast Cancer Res Treat Date: 2022-02-22 Impact factor: 4.872
Authors: Lauren Turza; Leann A Lovejoy; Clesson E Turner; Craig D Shriver; Rachel E Ellsworth Journal: Front Oncol Date: 2022-08-26 Impact factor: 5.738